World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
60
Citations
12716
World Ranking
3332
National Ranking
1546

Anthony T. Reder publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Anthony T. Reder sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 209 publications — 38th percentile

38% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Anthony T. Reder D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Anthony T. Reder sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 60 D-Index — 33rd percentile

33% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Anthony T. Reder is affiliated with the University of Chicago in the United States. Their research is primarily situated within the field of Medicine, with significant contributions to subfields such as Pathology and Forensic Medicine, Neurology, Oncology, Immunology, and Molecular Biology.

Their work focuses extensively on Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Cytokine Signaling Pathways and Interactions, Immunotherapy and Immune Responses, as well as Polyomavirus and related diseases. Other research areas include Rheumatoid Arthritis Research and Therapies and Systemic Lupus Erythematosus Research.

They have published in a variety of prominent venues, including:

  • Neurology
  • Multiple Sclerosis Journal
  • Multiple Sclerosis and Related Disorders
  • CNS Drugs
  • Frontiers in Neurology

Frequent collaborators in their research include Lilyana Amezcua, Nancy Monson, Timothy Vartanian, Mitzi Williams, and Gregory F. Wu.

Recent papers documenting their research contributions are:

  • COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies, 2021, CNS Drugs
  • T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy, 2022, Multiple Sclerosis Journal

Other notable papers related to their research field, though not directly authored by them, provide context to the ongoing studies in multiple sclerosis:

  • Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial, 2021, Multiple Sclerosis Journal
  • Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis, 2021, Multiple Sclerosis Journal
  • Understanding humoral immunity and multiple sclerosis severity in Black, and Latinx patients, 2023, Frontiers in Immunology

Best Publications

  • Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Peter A. Calabresi;Ernst Wilhelm Radue;Douglas Goodin;Douglas Jeffery

  • Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

    Davide Maimone;Susan Gregory;Barry G.W. Arnason;Anthony T. Reder

  • Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis

    R. Zivadinov;A. T. Reder;M. Filippi;A. Minagar

  • Cytokines in the Vitreous of Patients With Proliferative Diabetic Retinopathy

    Ahmed M. Abu El Asrar;Davide Maimone;Peter H. Morse;Susan Gregory

  • Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

    Chris H. Polman;Antonio Bertolotto;Florian Deisenhammer;Gavin Giovannoni

  • Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

    K Genç;D L Dona;A T Reder

  • Neuroleukin: a lymphokine product of lectin-stimulated T cells.

    Mark E. Gurney;Brian R. Apatoff;Gregory T. Spear;Mark J. Baumel

  • Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

    D. S. Goodin;Elliot Frohman;B. Hurwitz;P. W. O'Connor

  • Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial.

    Rhonda R. Voskuhl;He Jing Wang;T. C.Jackson Wu;Nancy L. Sicotte

  • Varicella-zoster virus infections in patients treated with fingolimod: Risk assessment and consensus recommendations for management

    Ann M. Arvin;Jerry S. Wolinsky;Ludwig Kappos;Michele I. Morris

  • Glucocorticoid receptors in depression: relationship to the dexamethasone suppression test.

    G J Gormley;M T Lowy;A T Reder;V D Hospelhorn

  • Immunomodulatory activity of interferon-beta

    Lloyd H. Kasper;Anthony T. Reder

  • COMBINING BETA INTERFERON AND ATORVASTATIN MAY INCREASE DISEASE ACTIVITY IN MULTIPLE SCLEROSIS

    G. Birnbaum;B. Cree;I. Altafullah;M. Zinser

  • The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

    Samuel F. Hunter;James D. Bowen;Anthony T. Reder

  • The mast cells of the multiple sclerosis brain

    Mohamed Z.M. Ibrahim;Mohamed Z.M. Ibrahim;Mohamed Z.M. Ibrahim;Anthony T. Reder;Rola Lawand;Wafaa Takash

  • Glucocorticoid resistance in depression: the dexamethasone suppression test and lymphocyte sensitivity to dexamethasone.

    Lowy Mt;Reder At;Antel Jp;Meltzer Hy

  • Activated suppressor cell dysfunction in progressive multiple sclerosis.

    J P Antel;M B Bania;A Reder;N Cashman

  • Interferon effects on interleukin-10 secretion Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients ☆

    A.M. Porrini;D. Gambi;A.T. Reder

  • Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1

    Xuan Feng;Anthony L Petraglia;Michael Chen;Paul V Byskosh

  • Therapeutic role of beta-interferons in multiple sclerosis.

    Adil Javed;Anthony T. Reder

  • Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis.

    Joseph W. Karaszewski;Anthony T. Reder;Ricardo A Maselli;Margaret Brown

  • Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis.

    Thomas Liggett;Anatoliy Melnikov;Shilpa Tilwalli;Qilong Yi

  • Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

    A John Petkau;Richard A White;George C Ebers;Anthony T Reder

  • COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.

    Anthony T Reder;Diego Centonze;Maria L Naylor;Anjali Nagpal

Frequent Co-Authors

Jack P. Antel
Jack P. Antel McGill University
Barry G. W. Arnason
Barry G. W. Arnason University of Chicago
Douglas S. Goodin
Douglas S. Goodin University of California, San Francisco
George C. Ebers
George C. Ebers University of Oxford
Dawn Langdon
Dawn Langdon Royal Holloway University of London
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Fred D. Lublin
Fred D. Lublin Icahn School of Medicine at Mount Sinai
Mark S. Freedman
Mark S. Freedman Ottawa Hospital
Bianca Weinstock-Guttman
Bianca Weinstock-Guttman University at Buffalo, State University of New York
Herbert Y. Meltzer
Herbert Y. Meltzer Northwestern University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to diverse healthcare and scientific careers. For those interested in advancing clinical skills quickly, an accelerated nurse practitioner program offers a fast track to becoming advanced practice nurses, blending immunology knowledge with patient care expertise.

If you are new to the medical field, pursuing one of the best online BSN programs for non nurses might be ideal. These programs are designed to transition non-nursing graduates into nursing professionals, providing a strong foundation in biological sciences related to immunology.

For those seeking quicker entry into nursing, exploring accelerated nursing programs near me can provide accessible pathways with less competitive admission criteria, allowing you to integrate immunology studies into your nursing education sooner.

Similarly, easy admission LPN programs offer a practical route for becoming licensed practical nurses. These programs require minimal admission hurdles and build a solid clinical skillset, complementing immunology knowledge applicable in many healthcare settings.

Best Scientists Citing Anthony T. Reder

Trending Scientists